Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more
Cinclus Pharma Holding AB (publ) (J8P) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.109x
Based on the latest financial reports, Cinclus Pharma Holding AB (publ) (J8P) has a cash flow conversion efficiency ratio of -0.109x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-46.85 Million) by net assets (€429.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cinclus Pharma Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Cinclus Pharma Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cinclus Pharma Holding AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cinclus Pharma Holding AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hwa Sung Ind
KO:002460
|
0.345x |
|
ASG Corp
VN:ASG
|
N/A |
|
Ilshinstone
KO:007110
|
0.030x |
|
Thor Medical ASA
OL:TRMED
|
0.000x |
|
Lam Dong Mineral and Building Material JSC
VN:LBM
|
N/A |
|
AGTech Holdings Limited
PINK:AGTEF
|
-0.091x |
|
MAYO Human Capital Inc.
TWO:6738
|
-0.672x |
|
Gevelot
PA:ALGEV
|
0.028x |
Annual Cash Flow Conversion Efficiency for Cinclus Pharma Holding AB (publ) (2021–2024)
The table below shows the annual cash flow conversion efficiency of Cinclus Pharma Holding AB (publ) from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €555.33 Million | €-178.37 Million | -0.321x | -111.79% |
| 2023-12-31 | €-76.80 Million | €-209.19 Million | 2.724x | +279.92% |
| 2022-12-31 | €126.87 Million | €-192.08 Million | -1.514x | -155.36% |
| 2021-12-31 | €127.10 Million | €-75.35 Million | -0.593x | -- |